UNIVERSAL HEALTH REALTY INCOME TRUST Q3 FY2026 earnings call

• Strategic Priorities: Management highlighted three key priorities: expanding acute care capacity/outpatient access, integrating Talkspace, and advancing recertification at Laurel Ridge Treatment Center.
• Acute Care Expansion: Added 177 beds in Q2, with continued ramp-up expected through year-end. Opened one freestanding emergency department (FED) in Q3 and another in Q4. Ambulatory pipeline includes several new outpatient access points.
• Talkspace Integration: Completed acquisition on August 17. Phased integration focuses on: 1) deploying technology platforms for smoother care transitions; 2) establishing referral flows from UHS facilities to Talkspace; 3) developing flexible outpatient offerings like virtual intensive outpatient programs (IOP).
• Laurel Ridge Recertification: Working with regulatory authorities toward recertification, currently expected during 2027. Q3 financial impact aligned with July outlook assumptions.
• De Novo Hospital Ramp-Up: Palm Beach Gardens (Florida) startup losses improved monthly; expects acceleration in winter season. Cedar Hill (Washington, D.C.) operating losses remained sequential flat (excluding supplements); break-even now expected in H1 2027 due to slower physician practice development in the community.
• Operational Trends: Acute demand favorable. Behavioral health volumes increased relative to recent quarters. Labor trends moderated. Expense management disciplined. Health insurance exchange trends consistent with expectations.

Acute Care: Same-facility net revenue increased 4.7%. Excluding the health plan, same-facility net revenue rose 3.1%. Revenue per adjusted admission decreased 1.7% on a reported basis but was slightly positive when excluding out-of-period Medicaid supplemental benefits and exchange shifts; underlying rate growth is estimated at approximately 3%. Same-facility segment EBITDA declined 4.5% in reported terms but increased 2.9% excluding out-of-period supplemental program benefits. Adjusted admissions increased 4.9%, emergency department visits rose 4.6%, while surgeries decreased 0.7%. Behavioral Health: Same-facility net revenue increased 4.0%, driven by a 2.1% increase in revenue per adjusted patient day and a 2.1% increase in adjusted patient days. Salaries, wages, and benefits per adjusted patient day rose 3.6%, though this improved sequentially due to moderating headcount growth. The segment results included Talkspace (immaterial contribution for Q3) and startup losses from de novo projects.

• Reiterated the financial and operating forecast ranges issued in July for full-year 2026.
• Expects full-year 2026 results to be towards the lower end of these ranges due to slower-than-expected ramp-up at de novo hospitals and softer surgical trends.
• Full-year capital expenditures anticipated to be slightly below $1 billion; expects moderation to approximately $800 million beyond 2026 as large projects complete.
• Share repurchases remain active; $735 million authorization available as of September 30, 2026.
• Leverage target maintained within 2.0x to 3.0x range; ended quarter at 2.17x.
• No specific 2027 numerical guidance provided yet; comprehensive 2027 guidance to be released in February 2027.

• Regulatory & Payer Risks: Significant headwinds from reductions in Medicaid supplemental funding (estimated $175–$200 million impact in 2027). Potential impact of Medicaid work requirements remains uncertain, particularly regarding medical frailty exemptions. Health insurance exchange volume declines creating an estimated $15 million annualized headwind.
• Operational Execution Risks: Slower-than-expected maturation of de novo hospitals (Palm Beach Gardens and Cedar Hill) impacting margin improvement timing. Laurel Ridge Treatment Center continues to incur operating losses until recertification is achieved.
• Market Dynamics: Accelerated shift of surgical procedures to alternative settings (ASCs, physician offices), negatively affecting hospital procedural volumes and potentially emergency room coverage in certain specialties like GI.
• Litigation & Compliance: Non-recurring litigation costs and professional liability reserves associated with the Cumberland facility in Virginia.

Q: What are the primary puts/takes for 2027, specifically regarding DPP headwinds and exchange impacts?

A: CFO Steve Filton noted that 2027 will face significant headwinds from Medicaid supplemental payment reductions, estimated at $175–$200 million, largely due to prior-year amounts not repeating and initial OB-3 provider tax cuts. Additionally, an annualized second-half 2026 exchange run rate creates a $15 million headwind, with potential for further increases if enrollment drops more than expected. Medicaid work requirements pose another variable risk, though many patients may qualify for medical frailty exemptions.

Q: Why are the two de novo acute care hospitals ramping slower than expected?

A: Cedar Hill in Washington, D.C., faces structural challenges due to a historical lack of physician infrastructure in Ward 7/8; while UHS is building practices, their development takes time, delaying break-even to H1 2027. Palm Beach Gardens opened in summer (due to construction delays) rather than the busy winter season, causing a slower start, but volumes are improving monthly and are expected to accelerate with the seasonal peak.

Q: How does the company view the shift from surgical to medical admissions and its impact on pricing?

A: Management attributes the weaker surgical mix to an accelerated industry trend of shifting elective procedures to alternative settings like ASCs and physician offices, particularly in GI and orthopedics. This shift negatively skewed pricing trends. However, underlying acute care rate growth remains approximately 3%, which aligns with long-term sustainability targets, once adjusted for exchange impacts, out-of-period payments, and the med-surg mix pressure.

Q: What is the strategic value and timeline for Talkspace synergies?

A: CEO Mark Miller emphasized that Talkspace allows UHS to capture revenue synergies by referring existing inpatient/outpatient patients to Talkspace for lower-acuity care, while Talkspace patients requiring higher levels of care are referred back to UHS. CFO Steve Filton stated that the transaction is expected to be slightly accretive in the first 12 months, with the bulk of revenue synergies materializing over the next 12–24 months as integration workflows and technology platforms mature.

Q: What are the capital expenditure priorities after the current de novo cycle?

A: CFO Steve Filton clarified that while CapEx will decline from ~$1 billion to ~$800 million post-2026, this is not purely maintenance. Approximately $250–$300 million covers maintenance, while the remaining $500–$550 million funds expansionary projects, including new beds, ORs, ERs, robotics in acute care, and continued investment in outpatient access points across both segments.